Protective effect of resveratrol against acute lung injury induced by lipopolysaccharide via inhibiting the myd88‑dependent Toll-like receptor 4 signaling pathway

Zhang,Zhuo; Chen,Ni; Liu,Jin‑Bo; Wu,Jian‑Bo; Zhang,Jing; Zhang,Ying; Jiang,Xian

doi:10.3892/mmr.2014.2226

Protective effect of resveratrol against acute lung injury induced by lipopolysaccharide via inhibiting the myd88‑dependent Toll-like receptor 4 signaling pathway

Authors:
- Zhuo Zhang
- Ni Chen
- Jin‑Bo Liu
- Jian‑Bo Wu
- Jing Zhang
- Ying Zhang
- Xian Jiang
View Affiliations

Affiliations: Department of Pharmacology, Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Research Centre of Medicine and Functional Foods, Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Clinical Laboratory, The First Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Anesthesiology, The First Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China
Published online on: May 9, 2014 https://doi.org/10.3892/mmr.2014.2226
Pages: 101-106

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol, a polyphenol mainly present in grapes and red wine, demonstrated varied pharmacological activities. The protective effects of resveratrol on acute lung injury (ALI) induced by lipopolysaccharide (LPS) have remained elusive. The present study investigated whether the protective effect of resveratrol on ALI induced by LPS was via inhibiting the myeloid differentiation primary response gene (myd88)‑dependent toll‑like receptor (TLR)4 signaling pathway. Mice were pretreated with 5 or 45 mg/kg resveratrol for three days prior to bronchial perfusion with 25 mg/kg LPS. At 12 h after surgery, the ratio of the wet to the dry (w/d) lung was calculated to assess tissue edema. Histological changes of the lungs were detected using hematoxylin and eosin staining and the protein expression levels of TLR4, myd88 and nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑κB) were measured by western blot analysis. The concentration of interleukin (IL)‑6 and cyclooxygenase (COX)‑2 in the bronchoalveolar lavage fluid were detected by ELISA. The results showed that resveratrol can suppress the edema, inﬂammatory cell inﬁltration and alveolar structure damage of lungs in mice with ALI and decrease the lung w/d ratio. Additionally, resveratrol markedly decreased the expression of TLR4, myd88 and NF‑κB and decreased the concentration of inﬂammatory cytokines, including IL‑6 and COX‑2. Therefore, it can be concluded that resveratrol has a protective effect against ALI induced by LPS, at least in part by inhibiting the myd88‑dependent TLR4 signaling pathway. In conclusion, resveratrol pretreatment has a protective effect against LPS‑induced ALI in mice, which indicates that resveratrol may serve as a potential therapeutic agent for treating ALI in the clinic.

View Figures

View References

1	Li T, Zhang J, Feng J, Li Q, Wu L, Ye Q, Sun J, Lin Y, Zhang M, Huang R, Cheng J, Cao Y, Xiang G, Zhang J and Wu Q: Resveratrol reduces acute lung injury in a LPS-induced sepsis mouse model via activation of Sirt1. Mol Med Rep. 7:1889–1895. 2013.PubMed/NCBI
2	Cabrera-Benitez NE, Pérez-Roth E, Casula M, Ramos-Nuez A, Ríos-Luci C, Rodríguez-Gallego C, Sologuren I, Jakubkiene V, Slutsky AS, Padrón JM and Villar J: Anti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury model. PLoS One. 7:e484682012. View Article : Google Scholar : PubMed/NCBI
3	Rubenfeld G, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ and Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med. 353:1685–1693. 2005. View Article : Google Scholar : PubMed/NCBI
4	Zhang XQ, Lv CJ, Liu XY, Hao D, Qin J, Tian HH, Li Y and Wang XZ: Genome-wide analysis of DNA methylation in rat lungs with lipopolysaccharide-induced acute injury. Mol Med Rep. 7:1417–1424. 2013.PubMed/NCBI
5	Devaney J, Contreras M and Laffey JG: Clinical review: gene-based therapies for ALI/ARDS: where are we now? Crit Care. 15:2242011. View Article : Google Scholar : PubMed/NCBI
6	Martínez O, Nin N and Esteban A: Prone position for the treatment of acute respiratory distress syndrome: a review of current literature. Arch Bronconeumol. 45:291–296. 2009.(In Spanish).
7	Nagaoka K, Takahara K, Tanaka K, Yoshida H, Steinman RM, Saitoh S, Akashi-Takamura S, Miyake K, Kang YS, Park CG and Inaba K: Association of SIGNR1 with TLR4–MD-2 enhances signal transduction by recognition of LPS in gram-negative bacteria. Int Immunol. 17:827–836. 2005.PubMed/NCBI
8	Wang X, Bi Z and Wang Y and Wang Y: Increased MAPK and NF-κB expression of Langerhans cells is dependent on TLR2 and TLR4, and increased IRF-3 expression is partially dependent on TLR4 following UV exposure. Mol Med Rep. 4:541–546. 2011.
9	Andonegui G, Zhou H, Bullard D, Kelly MM, Mullaly SC, McDonald B, Long EM, Robbins SM and Kubes P: Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest. 119:1921–1930. 2009.PubMed/NCBI
10	Diaz JV, Brower R, Calfee CS and Matthay MA: Therapeutic strategies for severe acute lung injury. Crit Care Med. 38:1644–1650. 2010. View Article : Google Scholar : PubMed/NCBI
11	Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
12	Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S and Hwang DH: Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol. 175:3339–3346. 2005. View Article : Google Scholar : PubMed/NCBI
13	Karpurapu M, Wang X, Deng J, Park H, Xiao L, Sadikot RT, Frey RS, Maus UA, Park GY, Scott EW and Christman JW: Functional PU.1 in macrophages has a pivotal role in NF-κB activation and neutrophilic lung inflammation during endotoxemia. Blood. 118:5255–5266. 2011.PubMed/NCBI
14	Zheng M, Chen R, Zhong H, Lin Q, Wang X, Zhao Z and Xie L: Side-effects of resveratrol in HepG2 cells: reduced pten and increased bcl-xl mRNA expression. Mol Med Rep. 6:1367–1370. 2012.PubMed/NCBI
15	Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R and Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444:337–342. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim SY, Park KC, Kwon SB and Kim DS: Hypopigmentary effects of 4-n-butylresorcinol and resveratrol in combination. Pharmazie. 67:542–546. 2012.PubMed/NCBI
17	Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR and Kim AL: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kim MY: Nitric oxide triggers apoptosis in A375 human melanoma cells treated with capsicin and resveratrol. Mol Med Rep. 5:585–591. 2012.PubMed/NCBI
19	Li W, Dai S, An J, Li P and Chen X: Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience. 151:1198–1207. 2008. View Article : Google Scholar : PubMed/NCBI
20	Li J, Zhao L, He X, Zeng YJ and Dai SS: Sinomenine protects against lipopolysaccharide-induced acute lung injury in mice via adenosine A(2A) receptor signaling. PLoS One. 8:e592572013. View Article : Google Scholar : PubMed/NCBI
21	Rogerio AP, Fontanari C, Borducchi E, Keller AC, Russo M, Soares EG, Albuquerque DA and Faccioli LH: Anti-inflammatory effects of Lafoensia pacari and ellagic acid in a murine model of asthma. Eur J Pharmacol. 580:262–270. 2008. View Article : Google Scholar : PubMed/NCBI
22	Frenzel J, Gessner C, Sandvoss T, Hammerschmidt S, Schellenberger W, Sack U, Eschrich K and Wirtz H: Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry. PLoS ONE. 6:e255442011. View Article : Google Scholar : PubMed/NCBI
23	Li J, Zhao L, He X, Zeng YJ and Dai SS: Sinomenine protects against lipopolysaccharide-induced acute lung injury in mice via adenosine A2A receptor signaling. PLoS ONE. 8:e592572013. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, He H, Li D, Zhu W, Duan K, Le Y, Liao Y and Ou YW: The role of the TLR4 signaling pathway in cognitive deficits following surgery in aged rats. Mol Med Rep. 7:1137–1142. 2013.PubMed/NCBI
25	Zhou J, Zhang X, Zhang H, Jia Y, Liu Y, Tang Y and Li X: Use of data mining to determine changes in the gene expression profiles of rat embryos following prenatal exposure to inflammatory stimulants. Mol Med Rep. 8:95–102. 2013.PubMed/NCBI
26	Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF and Xie LP: Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 101:488–493. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kim MH, Yoo DS, Lee SY, Byeon SE, Lee YG, Min T, Rho HS, Rhee MH, Lee J and Cho JY: The TRIF/TBK1/IRF-3 activation pathway is the primary inhibitory target of resveratrol, contributing to its broad-spectrum anti-inflammatory effects. Pharmazie. 66:293–300. 2011.PubMed/NCBI
28	Hou HW, Li XG, Yan M, Hu ZQ and Song YE: Increased leukocyte Rho-kinase activity in a population with acute coronary syndrome. Mol Med Rep. 8:250–254. 2013.PubMed/NCBI
29	Wheeler AP and Bernard GR: Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 369:1553–1564. 2007. View Article : Google Scholar : PubMed/NCBI
30	Teng P, Li YH, Cheng WJ, Zhou L, Shen Y and Wang Y: Neuroprotective effects of Lycium barbarum polysaccharides in lipopolysaccharide-induced BV2 microglial cells. Mol Med Rep. 7:1977–1981. 2013.PubMed/NCBI
31	Knapp S, Florquin S, Golenbock DT and van der Poll T: Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol. 176:3189–3195. 2006. View Article : Google Scholar : PubMed/NCBI
32	Bachmaier K, Toya S, Gao X, Triantafillou T, Garrean S, Park GY, Frey RS, Vogel S, Minshall R, Christman JW, Tiryppathi C and Malik AB: E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury. Nat Med. 13:920–926. 2007. View Article : Google Scholar : PubMed/NCBI
33	Shen Y, Wang Q, Zhao Q and Zhao J: Leptin promotes the immune escape of lung cancer by inducing proinflammatory cytokines and resistance to apoptosis. Mol Med Rep. 2:295–299. 2009.PubMed/NCBI
34	Medvedev AE, Lentschat A, Wahl LM, Golenbock DT and Vogel SN: Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol. 169:5209–5216. 2002. View Article : Google Scholar : PubMed/NCBI
35	Ware LB and Matthay MA: The acute respiratory distress syndrome. N Engl J Med. 342:1334–1349. 2000. View Article : Google Scholar : PubMed/NCBI